Navigation Links
GSI Group Inc. Schedules Earnings Release and Conference Call for Tuesday, March 12, 2013
Date:2/22/2013

BEDFORD, Mass., Feb. 22, 2013 /PRNewswire/ -- GSI Group Inc., (NASDAQ: GSIG) a global leader and supplier of  precision photonics, laser-based solutions and precision motion devices to the medical, industrial, scientific, and electronics markets, will release its fourth quarter 2012 results at 4:00 p.m. EST on Tuesday, March 12, 2013. 

(Logo: http://photos.prnewswire.com/prnh/20120305/NE64445LOGO )

The Company will host a conference call on Tuesday, March 12, 2013 at 5:00 p.m. EST to discuss these results. John A. Roush , Chief Executive Officer, and Robert Buckley , Chief Financial Officer, will host the conference call.  

To access the call, please dial (877) 482-5124 prior to the scheduled conference call time.  The conference ID number is 9406 4680.

A playback of this conference call will be available beginning 8:00 p.m. EST, Tuesday, March 12, 2013. The playback phone number is (855) 859-2056 or (404) 537-3406 and the code number is 9406 4680. The playback will remain available until 8:00 p.m. EST, Tuesday, March 26, 2013.

A replay of the audio webcast will be available four hours after the conclusion of the call on the Investor Relations section of the Company's web site at www.gsig.com

About GSI Group Inc.

GSI Group Inc. supplies precision photonics, laser-based solutions and precision motion devices to the medical, industrial, scientific, and electronics markets. GSI Group Inc.'s common shares are quoted on NASDAQ (GSIG).

More information about GSI is available on the Company's website at www.gsig.com. For additional information, please contact GSI Group Inc. Inv
'/>"/>

SOURCE GSI Group Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
2. Foundation Venture Capital Group Commits Second Round of Funding to Actinobac Biomed
3. Henry Schein Acquires The Maddox Practice Group
4. UBM Canon MedTech Group & DuPont Partner to Create Medical Packaging Innovation, Europes New Online Community for the Medical Device Packaging Industry
5. Aviir Secures Second $10 Million Financing Tranche; Attracts New Investor Group
6. The Access Group Wins Big in the 2012 Pharma Choice Awards
7. Ensuring Pharmaceutical Organizations are Effectively Organizing and Deploying Medical Science Liaisons across Diverse Customer Groups
8. Plaintiff in Prolift Vaginal Mesh Case Testifies She Can No Longer Work, Have Sex, or Function Normally, Rottenstein Law Group Reports
9. Millennium Research Group Identifies the Top Ten Trends in Medical Device Markets for 2013
10. Herborium(R) Group Discusses an Aftermath of the Ban of Diane-35 Acne Drug Due to Number of Deaths
11. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Akcea ... (NASDAQ: ISIS ), announced today that the ... Drug Designation to volanesorsen (ISIS-APOCIII Rx ) for ... (FCS).  FCS is a rare genetic disease characterized ... pancreatitis. In a Phase 2 study published in ...
(Date:7/5/2015)... , July 6, 2015 Nihon University ... symposium on Medical-Engineering Collaboration "Medicine Definitely Jumps ... 10, 2015 in Tokyo, Japan ... medical applied research will present their achievements and ... a new industry produced with 8K technology. ...
(Date:7/3/2015)... MUMBAI, India , July 4, 2015 /PRNewswire/ ... médicale continue cible les épidémies que sont l,hypertension, ... centrale et du Sud-Est, par l,intermédiaire de plateformes ... ces maladies.      (Photo: http://photos.prnewswire.com/prnh/20150630/227090 ... Prendre en charge le diabète en ligne , ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... Aug. 24 Curemark Founder and CEO Dr. Joan Fallon ... Sequencing 2009 Conference at Harvard Medical School on July 14th. ... this cutting-edge conclave is particularly significant, since epigenetics is the ... a change in the DNA sequence. Presenters at the session ...
... , EMERYVILLE, Calif., Aug. 21 ... NBY ), a clinical stage company developing non-antibiotic anti-infective compounds ... viral, and fungal infections, will deliver two poster presentations at the ... San Francisco, CA. The two poster presentations will describe results ...
Cached Medicine Technology:Curemark CEO Presents at Epigenomics Conference 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 2NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting 3
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Dr. Lawrence ... Washington, DC, area patients. Kybella is a non-surgical method to dissolve fat ... of reducing moderate to severe fat deposits under the chin, commonly known as a ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... Jeffrey R. Carlson finished his 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The ... Hospital in Newport News, VA. The procedure was an L5-S1 posterior lumbar interbody ...
(Date:7/6/2015)... ... ... Thanks to donations and a generous grant from the GAR Foundation, Senior ... patients and adult day center participants. , The Music & Memory program is committed ... families and volunteers. Music & Memory is a non-profit organization that helps provide patients ...
(Date:7/5/2015)... (PRWEB) , ... July 06, 2015 , ... ... ancillary benefits market, is excited to announce the next generation of PrimeStar Individual ... Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and usual, ...
(Date:7/5/2015)... ... July 05, 2015 , ... Women's Excellence in ... in Lake Orion. These classes are geared towards families that want their children ... break. , The fitness class will take place TUESDAYS at 4:30pm. Questions? ...
Breaking Medicine News(10 mins):Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... University in US are offering new insight into how ... ,Research from Brandeis University, which has been ... much needed insights into the probable shaping of the ... have provided new evidence towards the mechanisms that affect ...
... only when they affect only the diseased organs or cells ... to direct microcapsules into cancer cells and release their contents ... in releasing a substance into the tumour cell. They did ... directing it into the tumour cells where it gets “unpacked” ...
... improve quality of care, say researchers in this ... recently recommended //certification of doctors to strengthen professional ... in the United States that allows doctors to ... standards required for licensing purposes. Certified status must ...
... There are about three severe, potentially fatal genetic diseases ... can rupture in pregnancy and labor or even lesser ... blood vessel surgery and other approaches can be helpful, ... when they're offered. ,Now a large follow-up ...
... University researcher says that some religious activities may promote ... take notice and help their// community deal with the ... nation of gluttony and obesity, and churches are a ... professor of sociology who has studied religion and body ...
... restore healthy glucose levels and normal insulin action in obese ... published in the August 25 issue of Science and was ... (HSPH). ,Type 2 diabetes - 90 to 95 ... million people in the United States, and causes some 200,000 ...
Cached Medicine News:Health News:Research Reveal A New Angle On Neural Circuits. 2Health News:Microcapsules target cancer cells 2Health News:Microcapsules target cancer cells 3Health News:Certification of UK Doctors Would Improve Quality of Care 2Health News:Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date 2Health News:Scientists Review Loeys-Dietz Syndrome in the Largest Ever Study to date 3Health News:Religious Activities Could Promote Obesity 2Health News:Religious Activities Could Promote Obesity 3Health News:Religious Activities Could Promote Obesity 4Health News:Two Chemical Compounds Restore Healthy Glucose Levels In Obese Mice 2Health News:Two Chemical Compounds Restore Healthy Glucose Levels In Obese Mice 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: